in vivo bioavailability studies of sumatriptan succinate

in vivo bioavailability studies of sumatriptan succinate

In vivo bioavailability studies of sumatriptan succinate ...

In vivo bioavailability studies was also conducted in rabbits for optimized formulation using oral solution of sumatriptan succinate as standard. Results Bilayered buccal tablets (BBT) containing the mixture of Carbopol and HPMC K4M in the ratio 1:1 (T1) had the maximum percentage of in

In vivo bioavailability studies of Sumatriptan succinate ...

In vivo bioavailability studies was also conducted in rabbits for optimized formulation using oral solution of sumatriptan succinate as standard. ... The percentage relative bioavailability of ...

Development of in situ gel for nasal delivery: design ...

Sumatriptan succinate has oral bioavailability of 15% and undergoes hepatic metabolism, hence it is suitable for nasal administration. Objective: The objective of the investigation was to develop a mucoadhesive in situ gel to improve the bioavailability of the sumatriptan succinate.

(PDF) Development and In vivo Bioavailability Evaluation ...

PDF | In the present investigation an attempt has made to design mucoadhesive buccal tablets of sumatriptan succinate to improve its bioavailability.... | Find, read and cite all the research you ...

Preparation and in vivo evaluation of oral dissolving ...

The lower bioavailability of sumatriptan succinate is primarily because of presystemic first-pass metabolism and partly because of incomplete absorption [12]. In the present study an attempt was made to prepare oral dissolving films of sumatriptan succinate with the dose of 8

Development and Evaluation of in-situ Nasal Gel ...

Background: Sumatriptan succinate (SUT) is a potent drug used for relieving or ending migraine and cluster headaches. SUT bioavailability is low (15%) when it is taken orally owing to its gastric breakdown and bloodstream before reaching the target arteries.

In vivo bioavailability studies of sumatriptan succinate ...

Jan 01, 2011 · In vivo bioavailability studies was also conducted in rabbits for optimized formulation using oral solution of sumatriptan succinate as standard. Results Bilayered buccal tablets (BBT) containing the mixture of Carbopol and HPMC K4M in the ratio 1:1 (T1) had the maximum percentage of in vitro drug release within 6 hrs.

Shivanand K, Raju SA, Nizamuddin S, Jayakar B

In vivo bioavailability studies of sumatriptan succinate buccal tablets *1Shivanand K, 2Raju SA, 1Nizamuddin S, 3Jayakar B 1Acharya and B M Reddy College of Pharmacy, Bangalore-560090, India.2 HKE Society’s College of Pharmacy, Gulbarga-585105 (Karnataka), 3Vinayaka Mission’s College of Pharmacy, Salem (Tamil Nadu), India. Received 9 March 2011; Revised 18 June 2011; Accepted 19

Preparation and in vivo evaluation of oral dissolving ...

The lower bioavailability of sumatriptan succinate is primarily because of presystemic first-pass metabolism and partly because of incomplete absorption [12]. In the present study an attempt was made to prepare oral dissolving films of sumatriptan succinate with the dose of 8

Development and Evaluation of in-situ Nasal Gel ...

Dec 27, 2019 · Background: Sumatriptan succinate (SUT) is a potent drug used for relieving or ending migraine and cluster headaches. SUT bioavailability is low (15%) when it is taken orally owing to its gastric breakdown and bloodstream before reaching the target arteries.

Optimization of Sumatriptan Succinate Transdermal Emulgel ...

Ex-vivo diffusion study for batch F7 through goat skin indicated 88.68±2.52 % drug release. Statistical studies showed that drug release from the optimized formulation (F7) followed First order release kinetics. Conclusion: Sumatriptan succinate emulgel act as depot of drug which releases drug in controlled manner overcoming oral route side ...

In vitro and in vivo evaluation of the transdermal ...

In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. Patel SR (1), Zhong H, Sharma A, Kalia YN. Author information: (1)Vyteris, Inc., Fair Lawn, NJ, USA. The objective was to evaluate the transdermal delivery of the 5-HT (1B/1D) agonist, sumatriptan from an iontophoretic patch system, in vivo.

Fast-Dissolving Films of Sumatriptan Succinate: Factorial ...

Mar 22, 2015 · Sumatriptan succinate, a serotonin 5-HT agonist, commonly used for migraine has erratic absorption from the gastrointestinal tract following oral administration and undergoes first-pass metabolism, resulting in a low bioavailability. The present study was undertaken to formulate fast-dissolving films of sumatriptan succinate meant to be quickly dispersed in the mouth. Films were

Enhanced pharmacological efficacy of sumatriptan due to ...

Nov 01, 2018 · In vivo bioavailability studies of sumatriptan succinate buccal tablets. Daru 19 (3), 224–230 (2011). CAS PubMed PubMed Central Google Scholar

Development of a novel transdermal patch containing ...

Jan 01, 2014 · Development of a novel transdermal patch containing sumatriptan succinate for the treatment of migraine: ... in vivo pharmacokinetic studies indicated that SS was effectively absorbed from Nikasol patch through the skin and associated with relatively greater absolute bioavailability than that of oral administration. Therefore, these findings ...

In-vitro and in-vivo evaluation of Sumatriptan Succinate ...

Tayel, S. A., M. A. ElNabarawy, M. M. ElNabarawy, and M. H. H. AbouGhaly, "In-vitro and in-vivo evaluation of Sumatriptan Succinate Sublingual Dosage Forms", AAPS Conference, San Antonio, USA, 2013. ... Comparative Study Between Different Ready-Made Orally Disintegrating Platforms for the Formulation of Sumatriptan Succinate Sublingual Tablets ...

Sumatriptan succinate - DailyMed

Sumatriptan succinate is chemically designated as 3- [2- (dimethylamino) ethyl]-N-methyl-indole-5-methanesulfonamide succinate (1:1), and it has the following structure: The molecular formula is C 14 H 21 N 3 O 2 S•C 4 H 6 O 4, representing a molecular weight of 413.5. Sumatriptan succinate is a white to off-white powder that is readily ...

CENTER FOR DRUG EVALUATION AND RESEARCH

(Sumatriptan Succinate) autoinjector is a pre-filled, fully assembled single-use disposable auto-injector product containing 6 mg of sumatriptan (base) as the succinate salt delivered in a 0.5 mL subcutaneous dose. This product is intended for the acute treatment of migraine attacks with or without aura and the acute treatment of cluster

[PDF] FORMULATION AND EVALUATION OF BILAYER BUCCAL

Objective: To develop mucoadhesive bilayer buccal tablet of sumatriptan succinate to enhance its bioavailability and reduce its dosing frequency. Method: A batch prepared with ratio of HPMC K15: HPMC K100LV as 1:3, 4% Penetration enhancer, 40mg backing layer, compressed at 2 tons/cm2 for 10 s was identified as an ideal batch based on its buccal residence time and optimum mucoadhesive

Development of in situ gel for nasal delivery: design ...

Ex vivo studies on sheep nasal mucosa showed 93.33% within 5 h. In histopathological study, optimized batch was found to be safe and stable in accelerated stability study for three months. Optimized formulation, F7 has shown absolute bioavailability, which was found to be 164.70%. Drug targeting index for brain tissues was found to be 1.866.

Bioavailability Study to Compare OPTINOSE SUMATRIPTAN

Jan 11, 2012 · The purpose of this study is: To compare the single-dose pharmacokinetics (PK) of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.

FORMULATION AND EVALUATION OF FAST DISSOLVING

bioavailability of Sumatriptan Succinate is 14 ± 5 % owing to an important first pass metabolism. It has an elimination half-life of 2.5 hours and absorption zone from the upper intestinal tract. Plasma protein binding is low 14% to 21% 2. Sumatriptan Succinate. Fast Dissolving tablet, Direct compression, in vitro and in vivo disintegration time

In vitro and in vivo evaluation of the transdermal ...

May 01, 2007 · Transdermal delivery offers a convenient alternative, particularly where nausea prevents administration of an oral dosage form. In addition, sumatriptan has a relatively poor oral bioavailability (only 14%) and a relatively short half-life (T 1/2 ∼ 2 h) .However, based on the molecular properties of the weakly lipophilic sumatriptan base (log K o/w = 0.93 ; log D pH 7.4 = −1.3) it is ...

FORMULATION AND EVALUATION OF BILAYER BUCCAL

: Mucoadhesive bilayered buccal tablet of sumatriptan succinate may have enhanced bioavailability. A combination of polymer HPMC K15: HPMC K100LV in the ratio of 1:3 shows good mucoadhesive strength, ex-vivo drug release, and good mucoadhesive time. Keywords: Bilayer buccal tablet, Sumatriptan succinate, mucoadhesive strength, HPMC K100LV.

QBD APPROACH IN FORMULATION AND EVALUATION OF

Sumatriptan succinate is an antimigraine and pain inhibitory drug. Sumatriptan succinate has half‐life of 2.5 hrs. Its total bioavailability in the body is 06% due to first pass metabolism. Also Sumatriptan succinate is an acid sensitive that is readily reacts in the gastric environment thus reduces its oral bioavailability.

FORMULATION AND EVALUATION OF PRONIOSOME BASED

formulation and evaluation of Sumatriptan succinate proniosomal gels. Further ex-vivo permeation study was carried out to evaluate the feasibility of proniosomal gels for efficient delivery of Sumatriptan succinate. MATERIALS AND METHODS Sumatriptan succinate was a kind gift sample from Dr. Reddy’s laboratories, Hyderabad. Sorbitan

Bioequivalence Study of Sumatriptan Succinate Tablets 100 ...

Jan 04, 2011 · Open Label, Randomized, Two way crossover, comparative evaluation of relative bioavailability of two formulations of Sumatriptan Succinate Tablets 100 mg (Dr. Reddy's Laboratories Limited, India) With the Reference Formulation Imitrex® 100 mg Tablet (Glaxosmithkline, USA)Under Fed Conditions in Healthy Human Adult Subjects. 50 healthy, adult, human male subjects were enrolled in the study

FORMULATION AND EVALUATION OF FAST DISSOLVING TABLETS

May 01, 2013 · Sumatriptan Succinate is a 5-HT1D (5-hydroxy tryptamine 1D) receptor agonist, used in the treatment of migraine and cluster headache. It has low bioavailability due to its first pass metabolism. Hence the main objective of the study was to formulate fast dissolving tablets of Sumatriptan succinate to achieve a better dissolution rate and ...

Improvement of transdermal delivery of sumatriptan ...

sumatriptan succinate using novel water emulsion patch or self-dissolving microneedle array, and their in vitro and in vivo characterizations Dan WU Department of Biopharmaceutics, Kyoto Pharmaceutical University 2014 ..

This draft guidance, once finalized, will represent the ...

Waiver request of in vivo testing: 30 mg and 45 mg based on (i) acceptable bioequivalence (BE) studies on the 15 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths. See below for additional information regarding waivers of in vivo testing.

FORMULATION AND EVALUATION OF SUMATRIPTAN SUCCINATE NASAL ...

To improve the nasal retention time of Sumatriptan succinate, it has been formulated as in situ mucoadhesive gel by using Pluronic PF127 and carbopol 974P. The objective of this work was to improve the nasal bioavailability of Sumatriptan succinate by increasing its nasal retention time as well as by means of nasal permeation.

Mohamed AbouGhaly - Associate Professor - Faculty of ...

Sumatriptan succinate (SS) is a selective serotonin receptor agonist used for the treatment of migraine attacks, suffering from extensive first-pass metabolism and low oral bioavailability (∼14%).

Sumatriptan - FDA prescribing information, side effects ...

Dec 01, 2020 · Sumatriptan succinate, USP is a white to off‑white powder that is readily soluble in water and in saline. Each Sumatriptan tablet, USP for oral administration contains 35, 70, or 140 mg of Sumatriptan succinate, USP equivalent to 25, 50, or 100 mg of Sumatriptan, respectively.

Imitrex Tablets (sumatriptan succinate) dose, indications ...

However, only 0.24% (14 mcg; CI 6.1 to 22.7 mcg) of the 6 mg sumatriptan dose was recovered in the milk, which corresponds to a weight-adjusted mean exposure of 3.5% (95% CI 0.3% to 6.7%) of the maternal dose. Assuming oral bioavailability of sumatriptan in infants is similar to adults (mean 14%), the weight-adjusted infant dose is roughly 0.49%.